AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9460945 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 341
Study 7639229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with food
Number of subjects: 41
Study 7639229 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate without food
Number of subjects: 41
Study 2526419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (standard doses)
Number of subjects: 373
Study 2526419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (third dose late, >7 months after first dose)
Number of subjects: 373
Study 2526419 — intervention group
Group type: EXPERIMENTAL
Intervention: Various schedules of dose timing (early/late second and third doses)
Number of subjects: 373
Study 331502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumadizone calcium
Number of subjects: 56
Study 331502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 331502 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 56
Study 331502 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 56
Study 11952465 — intervention group
Group type: COMPARATOR
Intervention: 50 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Number of subjects: 251
Study 11952465 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Number of subjects: 251
Study 11952465 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction assessed by postnatal questionnaire.
Number of subjects: 251
Study 11952465 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for oral inducing agent if another induction is needed.
Number of subjects: 251
Study 29457873 — intervention group
Group type: EXPERIMENTAL
Intervention: Video endoscopic examination (VEE)
Number of subjects: 0
Study 29457873 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopic examination (SEE)
Number of subjects: 0
Study 27568303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 20
Study 27568303 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 24807325 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture closure
Number of subjects: 746
Study 24807325 — intervention group
Group type: COMPARATOR
Intervention: Staple closure
Number of subjects: 746
Study 23717118 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Number of subjects: 50
Study 23717118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23717118 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) in CT genotype of G protein beta 3 gene
Number of subjects: 50
Study 23717118 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) in Trp64/Arg genotype of beta 3 adrenergic receptor gene
Number of subjects: 50
Study 23717118 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) in DD genotype of angiotensin I converting enzyme gene
Number of subjects: 50
Study 20056980 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple incision method group (TIMG)
Number of subjects: 101
Study 20056980 — intervention group
Group type: COMPARATOR
Intervention: Swan neck catheter group (SNCG)
Number of subjects: 101
Study 18539195 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula
Number of subjects: 2252
Study 18539195 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula
Number of subjects: 2252
Study 18539195 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 2252
Study 18539195 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula (CMF)
Number of subjects: 2252
Study 16167646 — intervention group
Group type: EXPERIMENTAL
Intervention: International accreditation
Number of subjects: 51
Study 16167646 — intervention group
Group type: COMPARATOR
Intervention: Before trial
Number of subjects: 51
Study 16167646 — intervention group
Group type: EXPERIMENTAL
Intervention: After trial
Number of subjects: 51
Study 16167646 — intervention group
Group type: EXPERIMENTAL
Intervention: Accredited units
Number of subjects: 51
Study 16167646 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-accredited units
Number of subjects: 51
Study 12010707 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based instruction (n = 29)
Number of subjects: 94
Study 12010707 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based instruction (n = 32)
Number of subjects: 94
Study 12010707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined computer-based and lecture-based instruction (n = 33)
Number of subjects: 94
Study 12010707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (n = 33)
Number of subjects: 94
Study 10452771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk formula (1789 infants)
Number of subjects: 6209
Study 10452771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk (1859 infants)
Number of subjects: 6209
Study 10452771 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (1737 infants)
Number of subjects: 6209
Study 10452771 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breast-feeding (824 infants)
Number of subjects: 6209
Study 10452771 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to CM while in the hospital
Number of subjects: 6209
Study 10452771 — intervention group
Group type: EXPERIMENTAL
Intervention: Obvious parental atopy
Number of subjects: 6209
Study 7885287 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (average of 21 +/- 1 min.d-1 at 1.76 +/- 0.02 m.s-1)
Number of subjects: 26
Study 7885287 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained habitual lifestyle)
Number of subjects: 26
Study 2203140 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal tumor therapy
Number of subjects: 0
Study 364910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day) for 28 days
Number of subjects: 39
Study 364910 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 39
Study 364910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 39
Study 31026303 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHD using regional citrate anticoagulation and a high-cut-off dialyzer
Number of subjects: 60
Study 31026303 — intervention group
Group type: COMPARATOR
Intervention: CVVHD using regional citrate anticoagulation and a high-flux dialyzer
Number of subjects: 60
Study 28582393 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham equation with BMI
Number of subjects: 2056
Study 28582393 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham equation with lipids
Number of subjects: 2056
Study 28582393 — intervention group
Group type: COMPARATOR
Intervention: Early ART
Number of subjects: 2056
Study 25240168 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging pre- and post-stent implantation
Number of subjects: 29
Study 23575913 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative phase feedback training
Number of subjects: 22
Study 23575913 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed feedback training
Number of subjects: 22
Study 23575913 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip force feedback training
Number of subjects: 22
Study 23575913 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback training
Number of subjects: 22
Study 21625183 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment continued after diagnosis of BM
Number of subjects: 75
Study 21625183 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy for BM
Number of subjects: 75
Study 21625183 — intervention group
Group type: COMPARATOR
Intervention: First-line chemotherapy
Number of subjects: 75
Study 21625183 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) after diagnosis of MBC
Number of subjects: 75
Study 19927726 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil anaesthesia (Group PR)
Number of subjects: 40
Study 19927726 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and remifentanil anaesthesia (Group S)
Number of subjects: 40
Study 16703336 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative alone (group 1, n=10)
Number of subjects: 23
Study 16703336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enamel matrix derivative and bioactive glass (group 2, n=13)
Number of subjects: 23
Study 12658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) 0.3 IU/kg/day subcutaneously from day 3 before operation until day 7 after operation
Number of subjects: 20
Study 12658483 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 20
Study 12658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH)
Number of subjects: 20
Study 12658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) and Placebo
Number of subjects: 20
Study 10955339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) for RA
Number of subjects: 409
Study 10955339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) for OA
Number of subjects: 409
Study 10955339 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser for RA
Number of subjects: 409
Study 10955339 — intervention group
Group type: COMPARATOR
Intervention: Control group using opposite hand for RA
Number of subjects: 409
Study 10955339 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser for OA
Number of subjects: 409
Study 8820685 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosporin (2 x 10^9 microbial cells of Bacillus subtilis and Bacillus licheniformis)
Number of subjects: 0
Study 1431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CEA monoclonal antibody (F023C5) radioimmunoscintigraphy (RIS)
Number of subjects: 509
Study 1431344 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 509
Study 1431344 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 509
Study 1431344 — intervention group
Group type: COMPARATOR
Intervention: US
Number of subjects: 509
Study 3855601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in 1 mg dose
Number of subjects: 80
Study 3855601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in 2 mg dose
Number of subjects: 80
Study 3855601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in 3 mg dose
Number of subjects: 80
Study 3855601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaginal triacetin gel)
Number of subjects: 80
Study 30794143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated mobility technician-assisted ambulation
Number of subjects: 102
Study 30794143 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 102
Study 29663984 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP (intervention group)
Number of subjects: 120
Study 29663984 — intervention group
Group type: COMPARATOR
Intervention: CON (control group)
Number of subjects: 120
Study 26997458 — intervention group
Group type: EXPERIMENTAL
Intervention: URSA-S
Number of subjects: 168
Study 26997458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 24603216 — intervention group
Group type: EXPERIMENTAL
Intervention: Low activation music (LA/PV and LA/NV)
Number of subjects: 100
Study 24603216 — intervention group
Group type: COMPARATOR
Intervention: High activation/negative valence music (HA/NV)
Number of subjects: 100
Study 24603216 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 100
Study 22045925 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) for 6 months, measuring body weight, blood pressure, and heart rate daily with electronic devices.
Number of subjects: 160
Study 22045925 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) for 6 months.
Number of subjects: 160
Study 20101186 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (20 mg/kg/day)
Number of subjects: 268
Study 20101186 — intervention group
Group type: COMPARATOR
Intervention: Lithium (800 mg/day)
Number of subjects: 268
Study 20101186 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 268
Study 20101186 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 268
Study 18037769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (180 mg/day)
Number of subjects: 16
Study 18037769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16287384 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Parent Management Training intervention
Number of subjects: 73
Study 16287384 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 12099651 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 615
Study 10392392 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 T lead (steroid group)
Number of subjects: 95
Study 10392392 — intervention group
Group type: COMPARATOR
Intervention: 1451 T lead (nonsteroid group)
Number of subjects: 95
Study 10392392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both leads (1450 T and 1451 T)
Number of subjects: 95
Study 8728171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal minoxidil
Number of subjects: 21
Study 8728171 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil-free cycles
Number of subjects: 21
Study 1824736 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol (15‐g bolus followed by 15% infusion mixed in 75 mmol/L saline at 100 mL/h for 1 hour)
Number of subjects: 20
Study 1824736 — intervention group
Group type: COMPARATOR
Intervention: saline (equal volume of 75 mmol/L saline, intravenously)
Number of subjects: 20
Study 6341653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (CMD)
Number of subjects: 193
Study 6341653 — intervention group
Group type: COMPARATOR
Intervention: Cefmetazole (CMZ)
Number of subjects: 193
Study 31345387 — intervention group
Group type: EXPERIMENTAL
Intervention: reduced-dose chemoradiation (rdCRT) with 5600 cGy and weekly carboplatin
Number of subjects: 23
Study 31345387 — intervention group
Group type: COMPARATOR
Intervention: standard-dose chemoradiotherapy (sdCRT) with 7000 cGy
Number of subjects: 23
Study 28416009 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) conducting household visits using Lot Quality Assurance Sampling (LQAS) methodology.
Number of subjects: 4616
Study 28416009 — intervention group
Group type: COMPARATOR
Intervention: Community Health Workers (CHWs) in Luangwa high school.
Number of subjects: 4616
Study 28416009 — intervention group
Group type: COMPARATOR
Intervention: Community Health Workers (CHWs) in other teams.
Number of subjects: 4616
Study 26228291 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab (RBZ)
Number of subjects: 152
Study 26228291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab (RBZ)
Number of subjects: 152
Study 24072232 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Continuation
Number of subjects: 89
Study 24072232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 24072232 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus Responders
Number of subjects: 89
Study 21914410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal immunoglobulin in addition to standard treatment (group A)
Number of subjects: 70
Study 21914410 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (group B)
Number of subjects: 70
Study 18312768 — intervention group
Group type: COMPARATOR
Intervention: Combined simvastatin and ezetimibe treatment
Number of subjects: 1720
Study 16842145 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmacological approaches to improve vascular homeostasis, specifically targeting oxidative stress reduction or antioxidant defense augmentation.
Number of subjects: 0
Study 15160263 — intervention group
Group type: EXPERIMENTAL
Intervention: Perospirone 4 mg
Number of subjects: 20
Study 15160263 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg plus perospirone 4 mg
Number of subjects: 20
Study 15160263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15160263 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg
Number of subjects: 20
Study 10831905 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free 1% lignocaine
Number of subjects: 68
Study 10831905 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 68
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for chemo-sensitive tumors
Number of subjects: 0
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-sealed tube drainage and pleurodesis
Number of subjects: 0
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc slurry
Number of subjects: 0
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardiocentesis
Number of subjects: 0
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of drugs like doxycycline, OK-432, or bleomycin
Number of subjects: 0
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoraco-abdominal shunting and pleuro-pneumonectomy
Number of subjects: 0
Study 9369917 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous continuous drainage, pericardial fenestration, or pericardio-thoraco fenestration
Number of subjects: 0
Study 8419600 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture
Number of subjects: 0
Study 8419600 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen-oxygen mixture
Number of subjects: 0
Study 3512070 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy plus immunotherapy with Nocardia rubra cell-wall skeleton (N-CWS) and irradiated allogeneic AML cells
Number of subjects: 73
Study 3512070 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 73
Study 3512070 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy group
Number of subjects: 73
Study 2456566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30524633 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Therapy (CT) with lumbopelvic stability training (LPST)
Number of subjects: 16
Study 30524633 — intervention group
Group type: COMPARATOR
Intervention: Standard Massage Therapy (MT)
Number of subjects: 16
Study 28324268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 30 mg daily for 5 of 7 days plus dalotuzumab 10 mg/kg/week
Number of subjects: 62
Study 28324268 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg/day
Number of subjects: 62
Study 28324268 — intervention group
Group type: EXPERIMENTAL
Intervention: Any ridaforolimus dose
Number of subjects: 62
Study 28324268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg qd x 5 days/week
Number of subjects: 62
Study 28324268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 10 mg qd x 5 days/week
Number of subjects: 62
Study 25713953 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute, theory-based, safer sex intervention
Number of subjects: 400
Study 25713953 — intervention group
Group type: COMPARATOR
Intervention: Didactic time-equivalent attention control
Number of subjects: 400
Study 23833847 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60
Study 23833847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 23833847 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 60
Study 20462580 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based deep-breathing training
Number of subjects: 62
Study 20462580 — intervention group
Group type: COMPARATOR
Intervention: Weekly telephone support
Number of subjects: 62
Study 18250500 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 206
Study 18250500 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of care (CMC)
Number of subjects: 206
Study 16299259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2)) at 2.0 ATA for 2 hours
Number of subjects: 0
Study 16299259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2)) over 20 treatments
Number of subjects: 0
Study 16299259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2))
Number of subjects: 0
Study 16299259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO(2)) in mice
Number of subjects: 0
Study 15270890 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical paricalcitol ointment (15 microg g(‐1))
Number of subjects: 11
Study 15270890 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 11
Study 12067146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2T)
Number of subjects: 42
Study 9359979 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide (MOC; 400 mg daily)
Number of subjects: 95
Study 9359979 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline (NT; 75 mg daily)
Number of subjects: 95
Study 9359979 — intervention group
Group type: COMPARATOR
Intervention: placebo (PBO)
Number of subjects: 95
Study 8335816 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical exercise (mean energy expended: 1,876 ± 163 kcal/week)
Number of subjects: 62
Study 8335816 — intervention group
Group type: COMPARATOR
Intervention: Usual care (mean energy expended: 1,187 ± 97 kcal/week)
Number of subjects: 62
Study 3535008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin, 40‐160 mg daily
Number of subjects: 7
Study 3535008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7